All In Biotech

Drug Trial Radar · NCT02052310

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-Dialysis Patients

Last checked: Nov 19, 2026Latest source record: Oct 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,043 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,043

Actual

Start

Feb 11, 2014

Primary completion

Sep 21, 2018

Study completion Sep 21, 2018

Sponsor

Lead sponsor
Kyntra BioIndustry
Sponsor type
Industry
Collaborators
Astellas Pharma Europe B.V.; AstraZeneca
First posted
Feb 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants who have just begun dialysis treatment for ESRD.

Conditions

  • Anemia in Incident Dialysis Patients

Interventions

  • RoxadustatDrug

    Roxadustat will be administered per dose and schedule specified in the arm.

  • Epoetin AlfaDrug

    Epoetin alfa will be administered TIW according to the epoetin alfa USPI or SmPC, or local SOC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (ITT Population)Time frame: Baseline (Day 1, Week 0), Week 28 to 52
  2. Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (PPS Population)Time frame: Baseline (Day 1, Week 0) up to Week 24

Locations

113 sites in 15 countries. Site status is shown where the registry gives one.

  • Investigational Site

    Chula Vista, California

  • Investigational Site

    La Mesa, California

  • Investigational Site

    San Diego, California

  • Investigational Site

    Coral Springs, Florida

  • Investigational Site

    Lauderdale Lakes, Florida

  • Investigational Site

    Miami, Florida

  • Investigational Site

    Miami, Florida

  • Investigational Site

    Tampa, Florida

  • Meridian

    Meridian, Idaho

  • Investigational Site

    Shreveport, Louisiana

  • Investigational Site

    Detroit, Michigan

  • Investigational Site

    Pontiac, Michigan

  • Investigational Site

    Brookhaven, Mississippi

  • Investigational Site

    Columbus, Mississippi

  • Investigational Site

    Gulfport, Mississippi

  • Investigational Site

    Tupelo, Mississippi

  • Investigational Site

    Saint Ann, Missouri

  • Investigational Site

    St Louis, Missouri

  • Investigational Site

    Portsmouth, New Hampshire

  • Investigational Site

    Albuquerque, New Mexico

  • Investigational Site

    Durham, North Carolina

  • Investigational Site

    New Bern, North Carolina

  • Investigational Site

    Columbus, Ohio

  • Investigational Site

    Columbia, South Carolina

  • Investigational Site

    Orangeburg, South Carolina

  • Investigational Site

    Sumter, South Carolina

  • Investigational Site

    Knoxville, Tennessee

  • Investigational Site

    Edinburg, Texas

  • Investigational Site

    Houston, Texas

  • Investigational Site

    Houston, Texas

  • Investigational Site

    Serandi, Buenos Aires, Argentina

  • Investigational Site

    Santa Fe, IX Region, Argentina

  • Investigational Site

    Burgas, Bulgaria

  • Investigational site

    Dobrich, Bulgaria

  • Investigational site

    Pazardzhik, Bulgaria

  • Investigational site

    Pernik, Bulgaria

  • Investigational Site

    Pleven, Bulgaria

  • Investigational Site

    Plovdiv, Bulgaria

  • Investigational site

    Rousse, Bulgaria

  • Investigational Site

    Sofia, Bulgaria

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.